Thiophosphonoformic acid

Drug Profile

Thiophosphonoformic acid

Alternative Names: ANX-201; Pyrophosphate analogue - ADVENTRX Pharmaceuticals; Thiophosphonoformate; Thiovir; TPFA

Latest Information Update: 30 Oct 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Southern California
  • Class Antivirals
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Herpes simplex virus infections; HIV infections; Human papillomavirus infections; Influenza virus infections

Most Recent Events

  • 31 Mar 2008 Pharmacodynamics & pharmacokinetic data released by ADVENTRX Pharmaceuticals
  • 23 Jul 2007 Preclinical data added to the Viral Infections antimicrobial activity section ,
  • 07 May 2007 Preclinical data added to the Viral Infections antimicrobial activity section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top